Español  |  English
Home    |    Bioiberica People    |    Site Map    |    Contact  
About Bioiberica Products Bioiberica Structure News & Events
Bioiberica Links
Always on the move
The health website for sportsmen and women
Terra-Sorb
Product site for extensive cultivation care
Bioiberica Farma - Artrosis
The website of the Pharma - Osteoarthritis division
Bioiberica News
Trade news on plant physiology
Salud Mascotas
The website for the health of your pet
Plant Stress Management
Scientific platform on plant stress

Última actualización:
18 de mayo de 2012
PHARMA - OSTEOARTHRITIS NEWS

May 18, 2012
More than half of osteoarthritis patients attended by primary care physicians are at high risk of suffering gastrointestinal or cardiovascular problems
Osteoarthritis is a chronic inflammatory disease-it can be treated only during its acute phase.

Familial physicians attending the Úbeda symposium defended the efficacy and security of using SYSADOAs as the standard treatment of chronic osteoarthritis.

May 17, 2012
Osteoarthritis experts call for better coordination between various medical specialties, in order to improve patient care and reduce overall costs of the disease
Experts defend the efficacy and security of using SYSADOAs as standard treatment for chronic osteoarthritis

They agree that chondroitin sulfate improves patient’s life quality, reduces adverse effects, protects from cartilage volume loss and reduces the need for prostatic surgery

May 15, 2012
Osteoarthritis and osteoporosis, the most frequently diagnosed diseases at Reumasalud 2012
More than a hundred Aragonese visited the healthcare meeting point sited at the Centro Comercial Aragonia to get information and advice on rheumatic diseases

Dr. Eduardo Úcar, president of the Spanish Society of Rheumatology, inaugurated Reumasalud 2012 delivering a speech stressing the importance of early detection

April 26, 2012
New clinical trials prove that chondroitin sulfate may reduce synovitis and delay prosthetic surgery in osteoarthritis patients
A pioneering clinical trial coordinated by Dr. Jordi Monfort at the Hospital del Mar, Barcelona, has proved that, unlike paracetamol, chondroitin sulfate reduces inflammation and improves functional capacity.

Professor Jean-Pierre Pelletier will present the results of a clinical trial which provides evidence that patients receiving chondroitin sulfate treatment experience a lower risk of having to endure prosthetic surgery.

April 24, 2012
Bioiberica Farma presents Arthrosischip, a DNA-based test that predicts rapid progression of knee osteoarthritis
• It is DNA-based test that, using a simple saliva simple, can identify certain genetic alterations associated to osteoarthritis progression.

• Dr. Vergés said that “this tool could be used to identify and to give personalized treatment to severe OA cases and to assess the risks of prosthetic surgery, which in turn will lead to significant savings in health care expenditure”.

April 19, 2012
Bioiberica to present the results of the Arthrosischip Project, a DNA-based test that predicts the evolution of knee osteoarthritis using a simple saliva sample
• This new tool will allow for the personalization of osteoarthritis treatments, and will reduce the need for prosthetic surgery.

• The study’s results will be presented at the World Congress on Osteoarthritis, to be held in Barcelona, Spain, on April 25-29, 2012

March 30, 2012
Bioiberica Farma Launches “The Chondroprotection Blog”- an online discussion forum for osteoarthritis professionals
This blog contains up-to-date information on osteoarthritis-treatment, publications, latest advances in research. It is also an online discussion area that encourages the participation of all healthcare professionals.

It is hosted in the condroprotection.es website, a dedicated portal for healthcare professionals who specialize in osteoarthritis.

March 2, 2012
Loss of estrogens causes the association between osteoarthritis and menopause
Estrogens regulate a number of beneficial cellular processes in joint tissue. During menopause, the levels of estrogens decrease, thus leading to changes in the cartilage and subchondral bone

Osteoarthritis is a disease under-diagnosed among menopausal women that decreases their quality of life

It has been proposed a new classification of primary and/or idiopathic osteoarthritis that will take into account the deficit of estrogens

February 28, 2012
PROFARMA recognizes BIOIBERICA’s commitment to R&D
•Bioiberica is rated “good” and remains within the ‘A’ group, representing companies with significant research activity

•The Spanish chemical-pharmaceutical company, which employs 386 workers, has more than 58 R&D projects currently under development.

February 15, 2012
The Partnership between the FNIH and Bioibérica Farma will Boost Research on Osteoarthritis Biomarkers
Their new project focus on the research and validation of imaging and biochemical biomarkers used to diagnose knee osteoarthritis (OA) prior to the development of symptoms, to identify patient’s profiles, and to predict disease progression.

Biomarkers could be used to measure the efficacy of treatments, thus enabling the National Health System to save money.

The Foundation of the National Institutes of Health guarantees that the aim of this partnership is the improvement of the quality of life of OA patients by means of early diagnosis and personalized treatment.


1 2 3 4
Next Events
July 30, 2012
8th Meeting of the Working Group on Fruit Flies of the Western Hemisphere
Panamá City, Panamá,
30th July - 03th August, 2012

August 14, 2012
5th Workshop on the Characterization of Heparin Products
August 14–15, 2012, USP Headquarters, Meetings Center, Rockville, MD

+ More events
Home - Legal Notice - Privacy Policy - Site Map
Copyright 2012. Bioibérica. All rights reserved.